Skip to main content
WVE
NASDAQ Life Sciences

RA Capital Boosts Stake by $54.7M Following Positive Clinical Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$6.63
Mkt Cap
$1.246B
52W Low
$5.02
52W High
$21.73
52W Position info
32% above low
Off High info
69% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

WVE sits 32% above its 52-week low of $5.02.

Summary

RA Capital Management, a significant institutional investor and board member, increased its stake in Wave Life Sciences by approximately $54.7 million, bringing its total ownership to 17.5% of outstanding shares.


Key Events · Ownership and Investor Activity · WVE

  • Significant Insider Purchase

    RA Capital Management, L.P., and its affiliates, including board member Peter Kolchinsky, purchased approximately $54.7 million worth of Wave Life Sciences shares.

  • Increased Ownership Stake

    The purchases increased RA Capital's beneficial ownership to 34,225,506 shares, representing 17.5% of the company's outstanding common stock.

  • Post-Clinical Data Investment

    The transactions occurred between March 26 and March 30, 2026, immediately following the company's announcement of highly positive interim Phase 1 data for its investigational drug WVE-007 on March 26, 2026.

  • Strong Investor Confidence

    This substantial investment from a key institutional investor and board member indicates strong conviction in the company's recent clinical advancements and future potential.


Analysis · WVE · Life Sciences

This substantial investment by RA Capital, occurring immediately after the announcement of positive Phase 1 clinical data for WVE-007, signals strong conviction in Wave Life Sciences' pipeline and future prospects. The purchases, totaling over 4% of the company's market capitalization, demonstrate a significant vote of confidence from a major institutional holder with board representation, suggesting a belief that the recent clinical success will translate into long-term value. Investors should view this as a strong bullish signal, reinforcing the positive sentiment from the drug trial results.

At the time of this filing, WVE was trading at $6.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $5.02 to $21.73. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

WVE - Latest Insights

WVE
Jun 26, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.75
Real-time Price: $5.93 info
Change: +$0.180 (+3%) info
Market Cap: $1.139B info
WVE
May 18, 2026, 4:51 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.58
Real-time Price: $5.93 info
Change: -$0.650 (-10%) info
Market Cap: $1.139B info
WVE
May 18, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $6.62
Real-time Price: $5.93 info
Change: -$0.690 (-10%) info
Market Cap: $1.139B info
WVE
May 07, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $7.24
Real-time Price: $5.93 info
Change: -$1.31 (-18%) info
Market Cap: $1.139B info
WVE
May 01, 2026, 4:21 PM EDT
Filing Type: PRER14A
Importance Score:
8
Price at Filing: $7.32
Real-time Price: $5.93 info
Change: -$1.39 (-19%) info
Market Cap: $1.139B info